Orphacol ruling a blow for European Commission, but brings some legal clarity
This article was originally published in SRA
Executive Summary
The EU's General Court has annulled a decision by the European Commission to deny approval of Orphacol, a cholic acid-containing orphan drug for rare liver diseases produced by the French firm Laboratoires CTRS1. Among other things this means that the product can now receive an EU marketing authorization (MA).
You may also be interested in...
Changes To EU Orphan Similarity Concept Could Change Innovation Threshold For 10-Year Exclusivity
The European Commission has proposed changes to the existing criteria used for determining whether a new medicinal product is similar to an already authorized orphan drug and, therefore, whether it can be accepted for evaluation and granted 10-year market exclusivity.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.